Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced the continuation of its ambitious 2024 share repurchase program, now initiating an additional buyback of up to DKK 3.14 billion.

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed share transactions by its board members and executives, highlighting a significant purchase of 1,400 American Depositary Receipts ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

Ascendis Pharma and Novo Nordisk announced a partnership to develop cardiovascular and metabolic drugs that utilize Ascendis’ ...